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Abstract
Background and Aim: Thiopurines have a favorable beneﬁt–risk ratio in the treatment
of inﬂammatory bowel disease. A feared adverse event of thiopurine therapy is
myelotoxicity, mostly occurring due to toxic concentrations of the pharmacologically
active metabolites 6-thioguaninenucleotides. In oncology, myelosuppression has also
been associated with elevated 6-methylmercaptopurine (6-MMP). In this case series,
we provide a detailed overview of 6-MMP-induced myelotoxicity in inﬂammatory
bowel disease patients.
Methods: We retrospectively scrutinized pharmacological laboratory databases of ﬁve
participating centers over a 5-year period. Patients with leukocytopenia at time of
elevated 6-MMP levels (>5700 pmol/8 × 108 red blood cells) were included for detailed
chart review.
Results: In this case series, we describe demographic, clinical, and pharmacological
aspects of 24 cases of 6-MMP-induced myelotoxicity on weight-based thiopurine
therapy with a median steady-state 6-MMP level of 14 500 pmol/8 × 108 red blood cells
(range 6600–48 000). All patients developed leukocytopenia (white blood cell count
2.7  0.9 × 109/L) after a median period of 11 weeks after initiation of thiopurine
therapy (interquartile range 6–46 weeks). Eighteen patients (75%) developed concurrent
anemia (median hemoglobin concentration 6.9 × 109/L), and four patients developed
concurrent thrombocytopenia (median platelet count 104 × 109/L). Leukocytopenia
resolved in 20 patients (83%) within 4 weeks upon altered thiopurine treatment regimen,
and white blood cell count was increasing, but not yet normalized, in the remaining four
patients.
Conclusion: We observed that thiopurine-induced myelotoxicity also occurs because of
(extremely) high 6-MMP concentrations in patients with a skewed thiopurine
metabolism. Continued treatment with adapted thiopurine therapy was successful in
almost all patients.
Introduction
Thiopurines (i.e. azathioprine and mercaptopurine) are immuno-
suppressive drugs that play an indispensable therapeutic role in
maintaining remission in the majority of patients with inﬂamma-
tory bowel disease (IBD) (primarily Crohn’s disease and
ulcerative colitis).1–3 The complex metabolism of thiopurines
has been largely unraveled over the years, leading to the
observation that thiopurine S-methyl transferase (TPMT) plays
a pivotal role in the bioavailability of the pharmacologically
active end-metabolites: 6-thioguanine nucleotides (6-TGN,
therapeutic window 230–450 pmol/8 × 108 red blood cells
[RBC]) and 6-methylmercaptopurine (6-MMP, normal value
< 5700 pmol/8 × 108 RBC).4,5 Hepatotoxicity induced by
thiopurines is largely associated with the 6-MMP metabolites,
whereas myelotoxicity is mostly ascribed to high concentrations
of 6-TGN, leading to apoptosis and direct cytotoxicity due to
DNA strand breakage.6–8 However, when 6-MMP concentra-
tions are (extremely) high, as seen in high-dose thiopurine ther-
apy in oncological patients, or in IBD-patients with a skewed
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thiopurine metabolism (e.g. but not solely, caused by high
TPMT activity), 6-MMP can inhibit de novo purine synthesis,
thus causing subsequent myelotoxicity.4,9,10 Monitoring of
thiopurine metabolites (6-TGN and 6-MMP) in RBC and/or
TPMT mutation analysis is becoming integrated in general
IBD practice to optimize efﬁcacy and to minimize thiopurine
toxicity. Furthermore, when starting thiopurine therapy, it is ad-
vised to monitor laboratory parameters on a regular basis for
early detection of toxicity.2,3 Myelotoxicity caused by high 6-
MMP levels is believed to be an uncommon adverse event in
IBD patients.11–13 Here, we present 24 cases with 6-MMP-
induced leukocytopenia and describe subsequently applied strat-
egies to optimize thiopurine metabolism by preventing excessive
6-MMP generation.
Methods
Study design. The pharmacological laboratory databases of
three tertiary referral centers in the Netherlands (VU University
Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam;
andMaastricht UniversityMedical Center,Maastricht) and two large
teaching hospitals (Zuyderland Medical Center, Heerlen-Sittard-
Geleen and Máxima Medical Center, Veldhoven) were scrutinized
by an automated search over a time period of 5 years (January 1,
2011–December 31, 2015) for this retrospective study. Furthermore,
these databases were cross-checked with IBD databases on site.
Patient selection. The pharmacological reports of all
patients using thiopurines and having at least one metabolite
measurement in the selected time period were analyzed. We
included all IBD patients with 6-MMP concentrations above
5700 pmol/8 × 108 RBC for detailed chart review. Leukocytopenia
was deﬁned as white blood cell count below 4.0 × 109/L. Exclu-
sion criteria were the absence of leukocytopenia (i.e. white blood
cell count ≥ 4.0 × 109/L), 6-TGN concentrations (6-TGN) above
normal limits (i.e. > 450 pmol/8 × 108 RBC), the absence of a
skewed metabolism (i.e. 6-MMP/6-TGN ratio < 20) or the lack
of laboratory measurements within 3 days prior to or after metab-
olite measurement.
Demographic characteristics. At time of
leukocytopenia, we collected the following data on patient charac-
teristics: sex, age, weight, type of IBD, Montreal classiﬁcation,14
speciﬁc thiopurine derivative, dosage and duration of thiopurine
therapy, and concomitant medication, in particular drugs known
to induce myelosuppression by itself (e.g. allopurinol,15 ACE-
inhibitors,6 ribavirin,16 and mesalazine17,18) or interfere with
thiopurine metabolism. Treatment strategies following (allegedly)
6-MMP-induced leukocytopenia (i.e. discontinuation, dose-
reduction, allopurinol co-administration, or switch to thioguanine)
were evaluated. When patients were admitted to the hospital with
fever at time of diagnosed leukocytopenia, routine blood cultures
and virologic tests were assessed to rule out other causes (e.g. viral
infection or sepsis).
Laboratory tests. We collected the following hematologic
parameters from all included patients at time of diagnosed
leukocytopenia and 2–6 weeks after application of thiopurine opti-
mization strategy: white blood cell count (WBC; normal range
4.0–10.0 × 109/L), hemoglobin concentration (Hb; normal range
male 8.5–11.0 × 109/L, female 7.5–10.0 × 109/L), mean corpuscu-
lar volume (normal range 80–100 fL), platelet count (normal range
150–400 × 109/L), aspartate aminotransferase (reference value
male ≤ 35 U/L, female ≤ 40 U/L), and alanine aminotransferase
(reference value ≤ 55 U/L). Differentials of WBC were collected
when determined within 3 days after diagnosed leukocytopenia.
Furthermore, we collected thiopurine metabolites ([6-MMP] and
[6-TGN]) at time of myelotoxicity (within 3 days prior to or after
diagnosed leukocytopenia) and during follow-up (i.e. 2–6 weeks
after optimizing therapy), when available.
Concentrations of metabolites were measured using a previously
described method by Dervieux et al.19 or Lennard et al.20 The
Lennard method has found the greatest application in clinical
studies yet and has served as the basis for the establishment of
treatment-related therapeutic ranges for thiopurine therapy.21
Laboratory measurements of the Maastricht University Medical
Center and the Máxima Medical Center were performed in the
Zuyderland Medical Center. In the Zuyderland Medical Center,
concentrations of metabolites were measured using the method
described by Lennard until April 2013. From April 2013, the
method by Dervieux was applied. Concentrations of metabolites
in the other two centers were measured using the method described
by Dervieux. In these centers, concentrations of 6-TGN were
divided by a factor of 2.6 to make them comparable to those
determined by the Lennard method.22,23 Concentrations of
6-MMP are similar in both assays.21
Data analysis. All data are given descriptively or tabulated.
Data are expressed as median with interquartile range (IQR) or
range, or as mean with standard deviation according to distribu-
tion. Metabolite concentrations at baseline and after applying treat-
ment optimization strategies were compared using the Wilcoxon
signed-rank test. Correlations between nonparametric values were
measured using the Spearman’s rank order correlation test.
Ethical approval. This study was approved by the Medical
Ethics Review Committee of the VU University Medical Center
with ﬁle-number 2016-824.
Results
Patient characteristics. A total of 24 patients (50% male,
50% female) were included with a mean age at initiation of
thiopurine therapy of 44  18 years. Crohn’s disease and
ulcerative colitis were diagnosed in nine (38%) and 15 (62%)
patients, respectively. Median duration of thiopurine therapy until
development of myelotoxicity was 11 weeks (IQR 6–46). All
patient characteristics are summarized in Table 1.
Development of leukocytopenia. After a median period
of 11 weeks after initiation of thiopurine therapy, leukocytopenia
developed with a mean WBC of 2.7  0.9 × 109/L. In 18 patients
(75%), hemoglobin decreased under the lower reference limit to a
median of 6.9 × 109/L (range 3.2–8.4) simultaneously. Concurrent
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thrombocytopenia occurred in four patients (17%) with a median
of 104 × 109/L (range 79–132). Three patients developed
pancytopenia.
Median 6-MMP was 14 500 pmol/8 × 108 RBC (range 6600–
48 000) with therapeutic 6-TGN in nine patients (38%; mean con-
centration 196  98 pmol/8 × 108 RBC) In the other 15 patients,
6-TGN concentrations were lower than the therapeutic cut-off
level (i.e. < 235 pmol/8 × 108 RBC). The median 6-MMP/6-
TGN ratio was 102 (range 24–327). The 6-MMP/6-TGN ratio
was not correlated to WBC (P = 0.23), but there seemed to be a
trend towards lower WBC in patients with higher 6-MMP concen-
trations (r = 0.30, P = 0.08). An overview of these results is
depicted in Tables 2 and 3.
Four patients (nos 6, 15, 20, and 21) were admitted to the hos-
pital because of complicated myelotoxicity combined with fever,
deep anemia, and/or worsening of IBD. Of these patients, three
patients (nos 6, 15, and 21) were febrile and treated with intrave-
nous antibiotics per local protocol. One patient (no. 20) was ad-
mitted for blood transfusion (Hb 3.2 × 109/L) and received three
units of erythrocytes concentrate, after which the anemia re-
solved. Patient nos 15 and 20 were also admitted because of
worsening of IBD course and received an induction course of
prednisolone. In these patients, thiopurine treatment was immedi-
ately ceased.
White blood cell count differentials. As depicted in
Table 3, WBC differentials were available in 9/24 patients
(38%). In four patients, there was an isolated absolute neutropenia,
and in one patient, there was an isolated absolute lymphopenia. In
the other four patients, both neutrophil count and lymphocyte
count were decreased.
Alternative optimizing treatment strategies after
6-MMP induced leukocytopenia. Of all patients devel-
oping leukocytopenia on thiopurine therapy, 11 patients (45%)
received subsequent allopurinol 100 mg/day combined with the
original thiopurine in a reduced dose (25–33% of original dose),
leading to a normalization of 6-MMP to a median of
220 pmol/8 × 108 RBC (IQR 100–288; P < 0.01) in all patients.
Concentrations of 6-TGN did neither differ from pre-treatment
(6-TGN; median 206 vs 192 pmol/8 × 108 RBC, P = 0.54) in this
subgroup nor in the total group (median 188 vs 193 pmol/8 × 108
RBC, P = 0.95), but 6-MMP/6-TGN ratios decreased from a
median of 102 to 1.3 (P < 0.001) in the total group.
In ﬁve patients (21%), thiopurine therapy was switched into the
alternative thiopurine derivative thioguanine, which undergoes a
less complex metabolism without the formation of 6-MMP.
Four patients (17%) with mild myelotoxicity (nos 3, 4, 5, and
16) received a 50% dose reduction of the original thiopurine with
Table 1 Demographics of included patients
Nos Sex Age (years) D Montreal Drug Dose (mg/day) Weight (kg) Dose (mg/kg) Relevant co-meds Week of leukocytopenia†
1 F 55 CD A2L2B1 MP 50 64 0.8 none 1000
2 F 80 CD A3L1B2 MP 75 67 1.1 none 220‡
3 M 33 CD A2L3B1p MP 75 60 1.3 none 9
4 F 24 CD A2L1B2 MP 75 56 1.3 none 6
5 F 34 CD A2L3B1 MP 100 87 1.1 none 110
6 M 18 CD A2L1B1 MP 100 68 1.5 none 6
7 F 43 CD A2L3B1 MP 100 65 1.5 mesalazine 20
8 M 21 CD A1L3B1 MP 100 56 1.8 none 6
9 F 62 CD A3L2B1 AZA 150 72 2.1 lisinopril 4
10 F 26 CD A2L1B1 AZA 175 76 2.3 none 46
11 M 74 UC E3 MP 75 71 1.1 mesalazine 12
12 M 23 UC E3 MP 75 65 1.2 mesalazine 12
13 F 49 UC E3 MP 75 65 1.2 mesalazine 6
14 M 50 UC E3 MP 100 78 1.3 none 104
15 F 67 UC E2 MP 100 75 1.3 mesalazine 6
16 F 75 UC E2 MP 100 75 1.3 none 45
17 F 34 UC E3 MP 100 57 1.8 none 5
18 M 31 UC E2 MP 125 89 1.4 mesalazine 6
19 F 32 UC E3 MP 150 92 1.6 none 12
20 M 51 UC E3 MP 150 86 1.7 mesalazine 4
21 M 35 UC E3 MP 150 84 1.8 none 5
22 M 63 UC E1 AZA 125 67 1.9 none 156
23 M 51 UC E2 AZA 150 60 2.5 mesalazine 45
24 M 34 UC E3 AZA 200 87 2.3 mesalazine 9
†week of diagnosed leukocytopenia
‡Leukocytopenia developed 4 weeks after dose increase.
AZA, azathioprine, CD, Crohn’s disease, D, diagnosis, F, female, M, male, MP, mercaptopurine, UC, ulcerative colitis.
Relevant co-medications were deﬁned as mesalazine, sulfasalazine, ace-inhibitors, trimethoprim, indomethacin, and ribavirin.
Montreal classiﬁcation:14A: age at diagnosis—1: below 17 years, 2: 17–40 years, 3: above 40 years.L: location—1: ileal, 2: colonic, 3: ileocolic.B: behav-
ior—1: non-stricturing non-penetrating, 2: stricturing, 3: penetrating, p: perianal involvement.E: extent—1: proctitis, 2: left-sided colitis, 3: extensive
colitis.
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subsequent normalization of hematologic parameters. In three pa-
tients, 6-MMP and 6-TGN concentrations decreased (6-TGN to
suboptimal levels) after dose reduction, and in the other patients,
thiopurine metabolites were not measured.
In four patients (17%; nos 5, 6, 11, and 22), thiopurine therapy
was discontinued with normalization of hematologic parameters
shortly (respectively 21 and 30 days) after discontinuation.
Thiopurine therapy was not rechallenged in these patients, based
on patient’s request.
In 20 of 24 (83%) patients, leukocyte count normalized 4 weeks
after changing treatment regimen. In the remaining four patients,
WBC was not normalized yet but improved compared with the
initial leukocytopenia (Fig. 1). Anemia at initial presentation
resolved in 12/18 (67%) of patients and improved in the remaining
six patients. At follow-up, four patients (17%) had thrombocytope-
nia. No mortality was observed in our cohort. These results are
summarized in Table 4. Overall, restart with adapted thiopurine
therapy was successful in 20 of 24 (83%) patients.
6-Methylmercaptopurine concentrations were neither correlated
with the use of co-medication (i.e. mesalazine), nor with the dose
of thiopurine therapy in the different patients. The development of
leukopenia was not correlated with the use of co-medication.
Genotyping of the TPMT enzyme (i.e. wild-type *1/*1 vs
heterozygous/homozygous polymorphisms) was performed using
a polymerase chain reaction in seven patients at baseline (29%;
nos 2, 5, 7, 10, 16, 23, and 24). All these patients were carriers
of the wild-type TPMT genotype (*1/*1).
Discussion
In this case series, a detailed description of 24 patients developing
myelotoxicity on thiopurine therapy due to a skewed,
ultramethylating thiopurine metabolism, and their follow-up is
provided. In these patients, 6-MMP-induced leukocytopenia de-
veloped after a median of 11 weeks after initiation of thiopurine
therapy and resolved within 4 weeks upon altered treatment regi-
men in 83% of the patients. One case has been published before.11
Over recent years, metabolism of thiopurines in IBD patients
has been extensively investigated. Most dose-dependent adverse
events of thiopurines in IBD patients have been ascribed to two
metabolite groups, 6-MMP and 6-TGN. Thiopurine-induced
myelotoxicity is almost exclusively being described in relation to
grossly elevated 6-TGN levels, causing DNA strand breakage
leading to direct cytotoxicity and apoptosis of activated T-
lymphocytes.4,9 High 6-TGN concentrations are associated with
low TPMT activity caused by a mutant genotype, thus shifting
the balance between 6-MMP and 6-TGN formation. Besides toxic
6-TGN concentrations, 6-MMP in (extremely) high concentrations
can cause myelotoxicity as well, because of inhibition of de novo
purine synthesis.4,11,24 Purines are essential compounds in nucleic
Table 2 Laboratory parameters of patients developing myelotoxicity on thiopurine therapy because of high 6-methylmercaptopurine concentrations
CASE
At time of developing myelotoxicity
WBC (× 109/L) Hb (× 109/L) MCV (fL) PC (× 109/L) AST (U/L) ALT (U/L) 6-MMP 6-TGN 6-MMP/6-TGN ratio
1 2.2 7.5 122 194 130 88 19 000 139 137
2 3.7 7.1 97 294 27 38 12 500 58 216
3 3.2 8.4 101 152 - 30 13 000 296 44
4 2.7 7.7 - 225 - 100 12 000 212 57
5 3.6 4.9 - 167 - 30 36 500 139 263
6 1.7 6.8 89 234 20 36 33 000 173 173
7 2.3 6.3 112 203 - - 48 000 279 172
8 2.0 7.8 - 269 - 14 11 000 423 26
9 2.5 7.6 122 132 69 55 22 000 215 102
10 3.7 8.5 94 311 18 15 6600 85 78
11 3.5 6.6 110 79 51 50 7500 308 24
12 2.6 6.6 90 329 28 52 13 000 262 50
13 3.5 7.5 - 253 - 35 13 000 169 77
14 3.9 9.6 89 249 - 181 16 000 80 200
15 1.8 7.2 98 125 29 39 46 000 273 168
16 3.8 7.3 108 267 60 68 22 000 273 81
17 3.4 7.0 106 209 - 10 36 000 110 327
18 1.8 6.6 91 409 - 69 30 000 319 94
19 2.3 6.5 99 199 - 61 37 000 262 141
20 1.6 3.2 100 417 11 9 19 000 73 260
21 0.8 5.8 - 155 111 274 13 000 65 200
22 2.2 7.4 104 82 27 38 13 000 127 102
23 3.5 8.4 90 315 47 41 10 000 223 45
24 2.5 8.1 90 204 17 20 12 000 133 90
The symbol (-) means not available.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin concentration; MCV, mean corpuscular volume; PC, platelet count;
WBC, white blood cell count.
6-MMP, 6-methylmercaptopurine; 6-TGN, 6-thioguaninenucleotides (Lennard). Metabolite concentrations are displayed as pmol/8 × 108 red blood cells.
All hematologic parameters were determined at the time of metabolite measurement. These values do not have to be the lowest by deﬁnition.
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acids, needed for the generation of DNA.25 When thiopurines are
administered in high (oncological) dosages, the median time to de-
velop leukocytopenia is approximately ten days.26 In IBD, dosage
of thiopurine therapy is substantially lower because of another
mode-of-action, because the required effect is mainly anti-
apoptotic, instead of anti-metabolic.4 In the current analysis with
lower IBD dosages, in which high 6-MMP concentrations were
studied as a result of a skewed thiopurine metabolism, the median
time to leukocytopenia was 11 weeks.6
We observed that 11 (45%) patients who developed
myelotoxicity because of ultramethylation beneﬁtted from the
addition of allopurinol to a reduced (25–33%) dose of the original
thiopurine. Allopurinol is an inhibitor of the enzyme xanthine
oxidase and also has an indirect inhibiting function on TPMT
enzyme activity, thus leading to lower 6-MMP and higher 6-TGN
production.27–29 In addition, allopurinol seems to have an enhanc-
ing effect on hypoxanthine-guanine phosphoribosyltransferase
(HGPRT), contributing to higher 6-TGN formation as well.30,31
Additionally, ﬁve patients with leukocytopenia on conventional
thiopurine therapy beneﬁtted from a switch to thioguanine therapy,
hereby avoiding the formation of 6-MMP.32
As shown in a large prospective cohort study by Chaparro and
colleagues,33 leukocytopenia is witnessed in about 4% of the pa-
tients treated with thiopurines after a median period of 7 months.
This ﬁnding was underlined in a systematic review by Gisbert
et al.34 This effect is predominantly seen in patients with high
6-TGN concentrations (e.g. caused by heterozygote/homozygote
TPMT mutations or patients with a NUDT15 mutation), and inci-
dence is probably lower in patients with high 6-MMP levels.35–37
Recently, results of a prospective study showed that elevated
6-MMP and 6-TGN metabolites assessed one week after initiation
were independently associated with thiopurine-induced leukope-
nia.38 Furthermore, it was demonstrated that patients who show
excessive 6-MMP formation are also at risk for early thiopurine
failure because of intolerable adverse events or refractoriness.39
One of the limitations of our case series is the retrospective
nature. Another possible limitation is that patients in this cohort
were identiﬁed based on a skewed thiopurine metabolism, and
these results were linked to leukocytopenia afterwards. Because
therapeutic drug monitoring is not performed routinely in all pa-
tients of the participating centers, the total number of 6-MMP-
induced leukocytopenia might be higher than suggested in our
analysis. Unfortunately, differentials of WBC were available in
only 9/24 patients, because this measurement is not performed
per protocol in the participating centers. Only WBC differentials
within 3 days after diagnosed leukocytopenia were added to our
analysis. Interestingly, it is not clear why patients develop neutro-
penia and/or lymphopenia, as shown in our results. To our
Table 3 Differential effects on white cell line in patients with leukocytopenia and TPMT genotyping (when available)
Leukocyte differentiation
CASE WBC
(× 109/L)
Neutrophils (× 109/L) Lymphocytes (× 109/L) Eosinophils (× 109/L) Monocytes (× 109/L) TPMT
genotype[N 1.5–7.5] [N 1.0–3.5] [N < 0.5] [N 0.1–1.0]
[N 40–75%] [N 25–35%] [N 0–5%] [N 2–10%]
1 2.2 - - - - -
2 3.7 - - - - -
3 3.2 1.92 (60%) 0.96 (30%) 0.06 (2%) 0.20 (6%) -
4 2.7 - - - - -
5 3.6 - - - - *1/*1
6 1.7 0.54 (32%) 1.14 (68%) 0.00 0.02 (1%) -
7 2.3 - - - - *1/*1
8 2.0 - - - - -
9 2.5 1.21 (48%) 1.04 (42%) 0.07 (3%) 0.19 (7%) -
10 3.7 - - - - *1/*1
11 3.5 1.43 (41%) 1.47 (42%) 0.19 (5%) 0.34 (10%) -
12 2.6 1.12 (43%) 1.20 (46%) 0.13 (5%) 0.14 (5%) -
13 3.5 - - - - -
14 3.9 - - - - *1/*1
15 1.8 0.64 (36%) 0.97 (54%) 0.07 (5%) 0.09 (5%) -
16 3.8 - - - - *1/*1
17 3.4 - - - - -
18 1.8 1.13 (63%) 0.53 (29%) 0.02 (1%) 0.07 (4%) -
19 2.3 - - - - -
20 0.9† 0.46 (51%) 0.13 (14%) 0.22 (24%) 0.02 (2%) -
21 0.8 0.40 (50%) 0.34 (43%) 0.00 0.06 (7%) -
22 2.2 - - - - -
23 3.5 - - - - *1/*1
24 2.5 - - - - *1/*1
†3 days after initial diagnosed leukocytopenia
The symbol (-) means result unavailable.
Values expressed in bold are lower than reference values.
TPMT, thiopurine methyl-S-transferase, WBC, white blood cell count, *1/*1, wildtype genotype.
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Figure 1 Change in white blood cell count four weeks after optimizing thiopurine treatment. 6-MMP, 6-methylmercaptopurine. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
Table 4 Laboratory parameters of patients developing myelotoxicity on thiopurine therapy due to high 6-methylmercaptopurine concentrations after
changing treatment strategy
After changing treatment strategy
CASE
WBC (× 109/L) Hb (× 109/L) PC (× 109/L) 6-MMP 6-TGN Strategy
1 4.4 8.7 264 0 695 Thioguanine
2 4.9 7.2 254 0 140 Thioguanine
3 5.1 9.4 207 2800 215 Dose reduction
4 5.0 8.4 177 6800 173 Dose reduction
5 6.0 5.8 226 - - Discontinuation
6 9.5 9.1 146 760 0 Discontinuation
7 4.1 7.1 164 4500† 68 Thioguanine
8 5.6 9.0 318 310 273 Allopurinol‡
9 4.5 7.6 153 200 207 Allopurinol‡
10 4.0 8.7 264 - - Dose reduction
11 4.0 7.3 65 - - Discontinuation
12 5.1 7.6 247 280 188 Allopurinol‡
13 3.8 7.9 221 190 219 Allopurinol‡
14 4.0 8.5 228 254 204 Allopurinol‡
15 6.4 7.3 120 - - Allopurinol‡
16 4.7 8.0 240 < 100 538 Allopurinol‡
17 5.6 7.9 235 0 235 Thioguanine
18 11.9 8.2 395 240 327 Allopurinol‡
19 5.6 - - 1300† 27 Thioguanine
20 3.3 8.2 316 < 100 162 Allopurinol‡
21 4.5 9.6 229 < 100 62 Allopurinol‡
22 3.2 7.4 81 - - Discontinuation
23 5.7 8.5 345 880 46 Dose reduction
24 3.8 8.9 183 724 127 Allopurinol‡
†Detectable because mercaptopurine was only terminated recently.
‡Reduction of thiopurine dose (25–33%) combined with allopurinol 100 mg/day.
The symbol (-) means not available.
Hb, Hemoglobin concentration; PC, platelet count; WBC, white blood cell count.
6-MMP: 6-methylmercaptopurine; 6-TGN: 6-thioguaninenucleotides (Lennard). Metabolite concentrations are displayed as pmol/8 × 108 red blood cells.
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knowledge, there are no data available describing the relative inci-
dence of neutropenia or lymphopenia in thiopurine users.
In this cohort, we did not determine TPMT genotyping system-
atically. However, we expect all patients to have normal/high
TPMT activity (wild-type genotype), because 6-MMP formation
is mainly driven by TPMT activity. Whereas it has been de-
scribed that preferential 6-MMP production could occur in pa-
tients with TPMT mutations, we believe this will not be of
added value to this paper, because other risk factors, besides 6-
MMP, for developing leukocytopenia are not assessed in this
retrospective study.10 Furthermore, even though we ruled out
common causes of leukocytopenia (e.g. viral infection or sepsis),
it is not ruled out that other factors (e.g. hematologic or autoim-
mune disorders and deﬁciencies of dietary vitamins) might have
contributed to the development of leukocytopenia in these pa-
tients, especially in those patients with only marginal elevated
6-MMP concentrations.40
With this detailed case series, we underline that myelotoxicity
may also be caused by grossly elevated levels of 6-MMP. This is
added to what has previously been demonstrated, namely that
myelotoxicity is mainly caused by elevated cytotoxic levels of
6-TGN, the use of certain co-medications or intercurrent (viral)
infections. Our ﬁndings might also be an explanation for
unexplained leukocytopenia during thiopurine therapy without
genetic variations (e.g. TPMT or NUDT15 mutation).25,41,42
Conclusion
We demonstrated that leukocytopenia develops in patients with
(extremely) elevated concentrations of 6-MMP. Almost all
patients were successfully treated with allopurinol alongside
thiopurines or from a switch to thioguanine. Adapted thiopurine
therapy was successful in the majority of patients who devel-
oped leukopenia resulting from a skewed metabolism. As
myelotoxicity mainly seems to occur shortly after introduction
of thiopurine therapy, we stress the importance of therapeutic
drug monitoring in case of myelotoxicity, especially in the ﬁrst
weeks after initiation.
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